Neuvivo Submits NDA to FDA for Investigational ALS Treatment NP001

Published Date: 10 Oct 2024

The hope is that NP001 could potentially slow the progression of the disease through its unique immunologic mechanism.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

2.

'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

3.

24 months after radical prostateectomy, no PSA recurrence was observed when using apalutamide plus ADT.

4.

Modified personalized cancer vaccine generates powerful immune response

5.

Spouses of Cancer Patients May Be at Increased Risk of Suicide


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot